EGM Statement

12 Apr 2007 13:40

Fulcrum Pharma PLC12 April 2007 FULCRUM PHARMA PLC ("the Group" or "the Company") Statement from Extraordinary General Meeting ("EGM") Fulcrum Pharma plc (AIM:FUL), the drug development and regulatory servicescompany, today held its Extraordinary General Meeting at which all of theresolutions put to shareholders were duly passed. These resolutions enable Fulcrum to complete the acquisition of UnicusRegulatory Services Ltd. The acquisition of Unicus is the next important step inthe delivery of Fulcrum's strategic objective to become a leader in theprovision of pharmaceutical regulatory services. Unicus strengthens Fulcrum'sexisting regulatory consulting and electronic publishing services and brings newcapabilities in pharmacovigilance, product information management, regulatoryinterim management, coaching & development and training. The acquisition willenable these additional services to be provided directly to Fulcrum's clientsand expands Fulcrum's overall drug development capability. Fulcrum's Chairman, Prof. Sir Charles George, said: "Following our ExtraordinaryGeneral Meeting today we are pleased to report that trading continues in linewith expectations. The acquisition of Unicus is the next step towards becoming aleading provider of pharmaceutical regulatory services in Europe. I would liketo welcome the Unicus team to Fulcrum and look forward to offering a broader anddeeper range of drug development services to our clients worldwide." For further information, please contact: Fulcrum Pharma PLCJon Court, Chief Executive Tel: 0870 710 7152 Seymour PierceJonathan Wright Tel: 0207 107 9000 About Fulcrum Pharma plc Fulcrum Pharma plc is a drug development and regulatory services business thatprovides global expertise to achieve drug development and regulatory approvalmilestones. Fulcrum Pharma offers immediate access to a highly credible, integrateddevelopment team that provides strategic and operational leadership required toensure that new drugs move smoothly from discovery research to product approval Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange havingsuccessfully floated in March 2000. This information is provided by RNS The company news service from the London Stock Exchange